Separately, Zacks Investment Research cut shares of Immunic from a “hold” rating to a “sell” rating in a report on Friday, January 10th.
Shares of NASDAQ:IMUX opened at $9.12 on Friday. The stock has a market capitalization of $90.24 million, a PE ratio of -0.67 and a beta of 3.49. Immunic has a 1 year low of $6.20 and a 1 year high of $46.80. The firm has a fifty day moving average price of $9.02 and a 200 day moving average price of $10.22.
In other Immunic news, Director Duane Nash sold 4,400 shares of the business’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $6.96, for a total transaction of $30,624.00. Following the completion of the transaction, the director now owns 22,362 shares of the company’s stock, valued at approximately $155,639.52. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 67.94% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. acquired a new position in Immunic during the 2nd quarter worth $132,000. BlackRock Inc. acquired a new position in Immunic during the 2nd quarter worth $145,000. Finally, Renaissance Technologies LLC lifted its position in Immunic by 44.3% during the 4th quarter. Renaissance Technologies LLC now owns 60,631 shares of the company’s stock worth $588,000 after acquiring an additional 18,602 shares during the last quarter. 14.83% of the stock is owned by hedge funds and other institutional investors.
Immunic, Inc, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis.
Recommended Story: Book Value Per Share in Stock Trading
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.